当前位置: X-MOL 学术J. Transl. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Journal of Translational Medicine ( IF 6.1 ) Pub Date : 2019-12-26 , DOI: 10.1186/s12967-019-02182-1
Sara I Pai 1 , Ezra E W Cohen 2 , Derrick Lin 1, 3 , George Fountzilas 4 , Edward S Kim 5 , Holger Mehlhorn 6 , Neus Baste 7 , Daniel Clayburgh 8 , Loren Lipworth 9 , Carlo Resteghini 10 , Nawar Shara 11 , Takashi Fujii 12 , Jun Zhang 13 , Michael Stokes 14 , Huifen Wang 15 , Philip Twumasi-Ankrah 15 , Sophie Wildsmith 16 , Asud Khaliq 15 , Giovanni Melillo 15 , Norah Shire 15
Affiliation  

BACKGROUND Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is controversial. This study investigates whether tumoral expression of PD-L1 is a prognostic marker in patients with recurrent and/or metastatic (R/M) HNSCC treated with standard chemotherapy. METHODS This retrospective, multicenter, noninterventional study assessed PD-L1 expression on archival R/M HNSCC tissue samples using the VENTANA PD-L1 (SP263) Assay. PD-L1 high was defined as PD-L1 staining of ≥ 25% TC, with exploratory scoring at TC ≥ 10% and TC ≥ 50%. The primary objective of this study was to estimate the prognostic value of PD-L1 status in terms of overall survival (OS) in patients with R/M HNSCC. RESULTS 412 patients (median age, 62.0 years; 79.9% male; 88.2% Caucasian) were included from 19 sites in seven countries. 132 patients (32.0%) had TC ≥ 25% PD-L1 expression; 199 patients (48.3%) and 85 patients (20.6%) had TC ≥ 10% and ≥ 50%, respectively. OS did not differ significantly across PD-L1 expression (at TC ≥ 25% cutoff median OS: 8.2 months vs TC < 25%, 10.1 months, P = 0.55) or the ≥ 10% and ≥ 50% cutoffs (at TC ≥ 10%, median OS: 9.6 months vs TC < 10%, 9.4 months, P = 0.32, and at TC ≥ 50%, median OS 7.9 vs TC < 50%, 10.0 months, P = 0.39, respectively). CONCLUSIONS PD-L1 expression, assessed using the VENTANA PD-L1 (SP263) Assay, was not prognostic of OS in patients with R/M HNSCC treated with standard of care chemotherapies. Trial registration ClinicalTrials.gov, NCT02543476. Registered September 4, 2015.

中文翻译:

SUPREME-HN:一项回顾性生物标志物研究,评估PD-L1表达在头颈部复发和/或转移性鳞状细胞癌患者中的预后价值。

背景技术尽管通过免疫程序治疗的头颈鳞状细胞癌(HNSCC)作为预后因素,但肿瘤细胞(TCs)上的程序性细胞死亡配体-1(PD-L1)表达与存活率提高有关。这项研究调查了PD-L1的肿瘤表达是否为标准化疗治疗的复发和/或转移性(R / M)HNSCC患者的预后标志物。方法采用VENTANA PD-L1(SP263)分析方法对这项回顾性,多中心,非干预性研究评估了档案R / M HNSCC组织样品中PD-L1的表达。PD-L1高被定义为TC≥25%的PD-L1染色,在TC≥10%和TC≥50%时进行探索性评分。这项研究的主要目的是根据R / M HNSCC患者的总生存期(OS)评估PD-L1状态的预后价值。结果来自七个国家19个地区的412例患者(中位年龄为62.0岁;男性为79.9%;白种人为88.2%)。132例(32.0%)的TC≥25%PD-L1表达; TC≥10%和≥50%的患者分别为199例(48.3%)和85例(20.6%)。OS在PD-L1表达之间无显着差异(TC≥25%截止中值OS:8.2个月vs TC <25%,10.1个月,P = 0.55)或≥10%和≥50%截止(TC≥10 %,中位OS​​:9.6个月vs TC <10%,9.4个月,P = 0.32,在TC≥50%时,中位OS​​ 7.9 vs TC <50%,10.0个月,P = 0.39)。结论使用VENTANA PD-L1(SP263)分析评估了PD-L1表达,经标准护理化学疗法治疗的R / M HNSCC患者不能预后OS。试用注册ClinicalTrials.gov,NCT02543476。2015年9月4日注册。
更新日期:2019-12-27
down
wechat
bug